Wellington Management Group LLP Has $205.23 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Wellington Management Group LLP decreased its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 6.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,376,961 shares of the company's stock after selling 519,671 shares during the quarter. Wellington Management Group LLP owned approximately 9.27% of Akero Therapeutics worth $205,227,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. AlphaQuest LLC boosted its position in Akero Therapeutics by 32,588.0% during the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock worth $227,000 after purchasing an additional 8,147 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Akero Therapeutics in the third quarter worth $265,000. XTX Topco Ltd bought a new stake in shares of Akero Therapeutics during the 3rd quarter worth $308,000. Sei Investments Co. acquired a new position in Akero Therapeutics in the 4th quarter valued at $303,000. Finally, KLP Kapitalforvaltning AS bought a new position in Akero Therapeutics in the 4th quarter worth $306,000.

Insider Buying and Selling

In related news, Director G. Walmsley Graham acquired 50,000 shares of the stock in a transaction dated Thursday, March 27th. The shares were bought at an average cost of $43.55 per share, for a total transaction of $2,177,500.00. Following the purchase, the director now owns 1,200,000 shares in the company, valued at approximately $52,260,000. This trade represents a 4.35 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Patrick Lamy sold 5,000 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $57.03, for a total value of $285,150.00. Following the completion of the transaction, the vice president now directly owns 33,492 shares of the company's stock, valued at approximately $1,910,048.76. The trade was a 12.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 341,309 shares of company stock valued at $15,863,578 and sold 242,135 shares valued at $12,064,779. Company insiders own 7.94% of the company's stock.

Remove Ads

Akero Therapeutics Stock Performance

Shares of AKRO traded down $0.76 on Monday, reaching $35.97. 2,550,969 shares of the stock traded hands, compared to its average volume of 841,113. The stock's 50-day moving average price is $47.10 and its 200-day moving average price is $35.66. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -9.59 and a beta of -0.18. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Equities analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on AKRO shares. Bank of America upgraded shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the company from $35.00 to $63.00 in a report on Thursday, January 30th. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. UBS Group lifted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Citigroup upped their price target on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Finally, HC Wainwright raised their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.